


# Accurate Fetal Variant Calling in the Presence of Maternal Cell Contamination

Elena Nabieva<sup>1,2</sup>, \*, Satyarth Mishra Sharma<sup>1,\*</sup>, Yermek Kapushev<sup>1</sup>, Sofya K. Garushyants<sup>1,2</sup>, Anna V. Fedotova<sup>1,3</sup>, Viktoria N. Moskalenko<sup>3</sup>, Ilya V. Kanivets<sup>4</sup>, Denis V. Pyankov<sup>4</sup>, Tatyana V. Neretina<sup>2,3</sup>, Maria D. Logacheva<sup>1,2,3</sup>, Georgii A. Bazykin<sup>1,2</sup>, and Dmitry Yarotsky<sup>1,2</sup>

<sup>1</sup>Skolkovo Institute of Science and Technology, Skolkovo, Russia.

<sup>2</sup>Institute for Information Transmission Problems (Kharkevich Institute), Russian Academy of Sciences, Moscow, Russia.

<sup>3</sup>Lomonosov Moscow State University, Moscow, Russia.

<sup>4</sup>Genomed LLC, Moscow, Russia

\*These authors contributed equally to this work.

Correspondence: [e.nabieva@skoltech.ru](mailto:e.nabieva@skoltech.ru)

High-throughput sequencing of fetal DNA is a promising and increasingly common method for the discovery of all (or all coding) genetic variants in the fetus, either as part of prenatal screening or diagnosis, or for genetic diagnosis of spontaneous abortions. In many cases, the fetal DNA (from chorionic villi, amniotic fluid, or abortive tissue) can be contaminated with maternal cells, resulting in the mixture of fetal and maternal DNA. This maternal cell contamination (MCC) undermines the assumption, made by traditional variant callers, that each allele in a heterozygous site is covered, on average, by 50% of the reads, and therefore can lead to erroneous genotype calls.

We present a panel of methods for reducing the genotyping error in the presence of MCC. All methods start with the output of GATK HaplotypeCaller on the sequencing data for the (contaminated) fetal sample and both of its parents, and additionally rely on information about the MCC fraction (which itself is readily estimated from the HTS data). The first of these methods uses an explicit formula based on simple probabilistic assumptions to “recalibrate” the fetal genotype calls produced by MCC-unaware HaplotypeCaller. The other two methods “learn” the recalibration model from examples. We use simulated contaminated fetal data to train and test the models. Using the test sets, we show that all three methods lead to substantially improved accuracy when compared with the original MCC-unaware HaplotypeCaller calls. We then apply the best-performing method to three chorionic villus samples from spontaneously terminated pregnancies.

## 1. Introduction

High-throughput sequencing of fetal DNA is increasingly being used in academic and clinical settings. It is a powerful tool with the potential for use in prenatal diagnosis based on chorionic villus or amniotic fluid sampling [13], or in the analysis of chorionic villi or products of conception for genetic diagnosis of an unsuccessful pregnancy. In prenatal diagnosis, whole-genome or whole-exome sequencing can discover novel clinically significant variants that are not present in SNP arrays or gene panels, resulting in higher diagnostic yield [1]. Prenatal sequencing can inform prenatal and postnatal care and counseling, and may lead to prenatal therapeutic interventions [1].

In standard practice, the DNA of both parents is sequenced together with fetal DNA (“trio sequencing”) in order to es-

tablish patterns of inheritance and inform variant prioritization and interpretation. A technical difficulty that may arise in the analysis of fetal DNA is the contamination of the fetal sample with maternal cells. The prevalence of such *maternal cell contamination* (MCC) can be significant, depending on the experimental technique and quality of the sample; for example, one study reported 9.1% of amniotic fluid samples as having detectable MCC [12], while another found MCC fraction > 5% in as many as 26% of amniotic fluid samples under some practices [15]. High-level contamination (over 20%) was detected by one study [9] in a small, but non-zero number of samples (0.3% of cultured amniotic fluid samples and 1.3% of cultured chorionic villi samples; it must be noted that cultured amniotic fluid samples generally have less MCC than direct samples). In traditional prenatal analysis, such as that aimed at detecting chromosomal aberrations, maternal cell contamination is assayed by special tests, such as the Short Tandem Repeat analysis, and, if detected at a sufficient level, may nullify the analysis [10].

Meanwhile, standard variant calling software that is used to analyze next-generation sequencing data relies on the expectation that each allele is represented by half of the reads. MCC disrupts this assumption, leading to errors in variant calling. In this work, we propose and evaluate computational methods for reducing the MCC-caused error. All of these methods begin with variants called in the fetal specimen, the mother, and the father by a standard variant-calling pipeline and then “recalibrate” the results from the fetal specimen. The first method uses a simple probabilistic heuristic to decide on the “true” fetal genotype based on the called genotypes of the trio. The other methods eschew making assumptions about the best way to uncover the “true” fetal genotype from the maternally-contaminated observed specimen data and instead solve this problem using machine learning. We train these methods on synthetic “mother-father-fetus” trios generated from real family trios by adding specified numbers of maternal reads to the child sample. We use these synthetic trios, where the child’s genotype is known, to demonstrate that MCC correction significantly improves the accuracy of variant calling compared to contamination-naïve calling, especially for higher fractions of MCC. As an intermediate technical step, we present a simple heuristic algorithm for estimating maternal cell contamination fraction in

the fetal sample. We then apply the trained model to real sequencing data from miscarried fetuses and their parents with  $MCC > 3\%$ , changing the fetal calls for a substantial number of SNPs.

## 2. Materials and Methods

In the rest of the paper, we use the term *specimen* to denote the obtained fetal sample which may be contaminated with maternal cells. In practice, it can be a chorionic villus or amniotic fluid sample or an abortus sample.

We assume that DNA samples are available for all three members of the trio. We expect the trio to be sequenced, and the reads mapped and variant-called according to a standard bioinformatics pipeline, e.g., one involving the Genome Analysis Toolkit (GATK, [5]), and that called genotypes are available along with accompanying quality information, such as allelic depths, genotype likelihoods, and so on. The VCF file produced by the pipeline is the starting point for all our analyses (see Figure 1).

**2.1. Estimating the contamination fraction.** We define the maternal cell contamination (MCC) fraction, which we denote by  $\alpha \in [0, 1]$ , to be the share of maternal DNA in the DNA of the fetal specimen. MCC accounts for the discrepancy between the results of variant calling on the contaminated specimen sample and the true fetal genotype. The MCC-aware variant calling and recalibration methods presented below all rely on knowing the value of  $\alpha$ , and therefore it is vital to be able to estimate it accurately.

To estimate  $\alpha$  in a fetal sample, we look at the results of variant calling by GATK HaplotypeCaller [5] and consider positions in the genome where the mother and the father are homozygous for different alleles (i.e., one of the parents is homozygous for the reference allele, and the other for the alternative allele); we only consider biallelic sites. The fetus then should be heterozygous at these sites, with equal read coverage for the two parental alleles.

In the presence of MCC, however, the mother's allele coverage fraction  $m$  should be higher, namely  $\frac{1+\alpha}{2}$ . Then, we can use the value of  $m$  at the position obtained from the VCF file to compute  $\alpha$  as  $2m - 1$ . Since the actual coverage fluctuates, we average this ratio over all relevant sites to get the MCC fraction estimate. Let  $m_i$  be the fraction of maternal reads at site  $i$ . Then we compute  $\hat{m}$  to be the average of  $m_i$  over all sites  $i$  where the mother and the father are homozygous for different alleles, and estimate  $\hat{\alpha} = 2\hat{m} - 1$ .

Although this procedure should be symmetric with respect to which of the parents is homozygous for the reference allele at a site, we observe that estimating  $\alpha$  when the mother is homozygous for the reference allele ("mo00") systematically gives larger values than when the mother is homozygous for the alternative allele ("mo11"). We attribute this phenomenon to the reference bias of the variant calling pipeline [6]. We, therefore, estimate  $\alpha$  separately over the two alternatives ("fa00\_mo11" and "fa11\_mo00") and compute the average of the two estimates as the final result. We found this


aggregated estimate to be more accurate than either alternative.

Using simulated data (see Section 2.4), we found that the MCC estimation error made by this method does not exceed 2% and in the vast majority of the cases is below 1% (Figure S1).

**2.2. Confidence interval-based recalibration.** As our first method, we consider a hypothesis-testing approach that carries out genotype call adjustment based on an explicit mathematical model. To construct the genotype prediction for the child, we first observe that the disagreement between the true variants of the child and the called variants of the fetal specimen is in the vast majority of cases due to the mislabeling of homozygous positions in the fetus as heterozygous in the contaminated fetal specimen. The maternal genotype must, of course, be heterozygous for that to happen. Following this observation, we set the recalibrated genotype prediction of the fetus to equal that of the contaminated specimen at all genome positions except for those where the contaminated specimen is called heterozygous, and mark these latter as candidates for readjustment to a homozygous call. At each site that is a candidate for readjustment, we compare the ratios of allelic depths in the mother and the fetal specimen to determine the homozygous readjustment target (00 or 11, with 0 denoting the reference allele and 1 denoting the alternative allele; only biallelic sites are considered). To check if the readjustment is indeed needed, we use the allelic depths of the fetal specimen,  $AD_0$  and  $AD_1$ , to estimate the DNA contamination ratio under the hypothesis that the child is homozygous and so the extra allele comes from the heterozygous mother; e.g.,  $\hat{\alpha}_{loc} = \frac{2AD_1}{AD_0+AD_1}$  when the candidate readjusted genotype is 00. Then we compare this value to the value of  $\hat{\alpha}$ , which we refer to here as  $\hat{\alpha}_{glob}$  (for "global"), estimated from the entire sample as described in Section 2.1 (for the present purpose, we view this latter value as exact). Using the binomial proportion confidence interval, we expect the site-specific contamination estimate

$\hat{\alpha}_{loc}$  to satisfy  $\hat{\alpha}_{glob} - z\sqrt{\frac{\hat{\alpha}_{glob}(1-\hat{\alpha}_{glob})}{AD_0+AD_1}} < \hat{\alpha}_{loc} < \hat{\alpha}_{glob} + z\sqrt{\frac{\hat{\alpha}_{glob}(1-\hat{\alpha}_{glob})}{AD_0+AD_1}}$ , where  $z$  is a parameter corresponding to the confidence level. We have chosen  $z = 3$  by tuning  $z$  experimentally to achieve a better prediction accuracy. If the contamination estimate at a site falls within the confidence interval, we attribute the heterozygosity observed at that site in the fetal specimen to maternal contamination and "correct" the call to be the appropriate homozygous genotype.

**2.3. Machine learning-based genotype recalibration.** In this approach, the predictive model for genotype readjustment is not based on heuristics, but is trained using a machine learning algorithm. The input to the model consists of two components. The first is the estimated fraction of maternal DNA in the fetal specimen,  $\hat{\alpha}_{glob}$ . The second is the vector of features characterizing the variants called in the fetal specimen and the parents at a particular position in the genome (practically, this is the line in the VCF file for that position;



**Fig. 1.** Pipeline for accurate fetal variant calling in the presence of maternal cell contamination (MCC). NGS reads for each sample in the trio are mapped to the reference genome, and then variants are called with GATK v3. In the presence of MCC, the resulting VCF file contains incorrect calls for the fetus. To overcome this, we estimate MCC from this VCF and utilize the estimated value to recalibrate the VCF file and correct the calls for the fetus. Three different approaches for recalibration were utilized (see Materials and Methods section): confidence intervals and two machine learning-based approaches, namely, logistic regression and Gradient Boosted Decision Trees (XGBoost). The meta-classifier combines outputs of all previous methods. ML - machine learning.

it includes the genotype likelihoods, genotype qualities, read depths, etc. for all three samples). The output of the model is the adjusted fetal genotype at this position in the genome.

The approach assumes that we either consistently use a particular mapping and variant calling pipeline or train predictive models using a sufficiently rich training dataset combining data obtained using several pipelines, since a single mapping and calling pipeline may have bias dependent on the specifics of the read mapper and variant caller. In practice, it is necessary that the fields describing the variant (genotype likelihood, read depth, etc.) be the same in the training VCFs and the VCF to be recalibrated; therefore, the same, or closely related variant callers should be used to produce all VCFs. The “ground truth” to which the predictive model is fit is the genotype calls on the pure fetal sample made by the same pipeline as was used on the fetal specimen sample. To train and test the model, we simulate “virtual specimens” from a number of publicly available father-mother-child trios by randomly mixing mother and child reads at various MCC fractions, as described in Section 2.4, and then calling the variants in the simulated trios. Since none of the trios on which the “virtual specimens” were based have MCC, we can use them to obtain the true child genotypes. The predictive model is then trained and tested on the data set that maps, genomic position-wise, father-mother-virtual specimen variant data to the child variant data of the corresponding father-mother-child sample. The predictive models may overfit to particular variant calling pipelines or underlying trios, and care must be taken to ensure sufficient diversity of training samples.

Two machine learning algorithms were considered: logistic regression (as implemented in `scikit-learn`<sup>1</sup>) and Gra-

dent Boosted Decision Trees (XGBoost implementation<sup>2</sup>, [2]). The inputs to the models are read from a VCF file and standardized, with categorical features being one-hot encoded (split into binary columns for each unique value the feature can take). L2 regularization is applied to the logistic models, while early stopping based on performance on a validation set is used to prevent XGBoost from overfitting. The hyperparameters of the models (regularization factor for logistic regression; maximum tree depth, etc. for XGBoost) were tuned using a grid search.

Additionally, an ensemble meta-classifier combining the results of all of the above methods (confidence intervals, logistic regression, XGBoost) was constructed. An ensemble makes predictions by combining ‘votes’ from multiple classifiers. Here we use soft-voting, i.e. voting based on the predicted probabilities of each class for the different classifiers, rather than a simple class prediction. This combined prediction helps mitigate the shortcomings of each individual classifier.

**2.4. Contaminated trio generation.** We obtained testing and training datasets by using publicly available exome reads from father-mother-child trios (“real-world trios”) to produce “virtual specimen trios” with predetermined maternal contamination fraction  $\alpha$ . Namely, we mixed randomly selected reads from the “real-world child” and the “real-world mother” in such a proportion that the fraction of maternal reads would be  $\alpha$ , and thus obtained “virtual specimen” reads. We used the remaining reads from the “real-world mother” to create the “virtual specimen mother”, while the “virtual specimen father’s” reads were identical to the original “real-world father’s” reads. For each “virtual specimen”

<sup>1</sup> <http://scikit-learn.org/>

<sup>2</sup> <https://xgboost.readthedocs.io/en/latest/>

trio, we also came up with a corresponding “pure child” trio, which was identical to the “virtual specimen” trio except that no mother’s reads were added to the child’s reads. Keeping everything but the presence of maternal contamination the same between the “virtual” and the “real” trios ensures that the genotypes called with and without contamination would be compared fairly.

We performed this procedure for four “real-world” trios with publicly available exome data: the Ashkenazim trio HG002\_NA24385 from the Genome in the Bottle project [16] (“AJT”), the YRI NA19240 trio from the 1000 Genomes project [3] (“YRI”), the CHD trio [7] (“CHD”), and the Corpas family daughter trio [4] (“Cortas”). Since the child in the “real-world” trios was either a living individual (AJT, YRI, Cortas) or stillborn (CHD), there was no maternal cell contamination in the “real-world” reads. If the data were available only as an alignment, we first obtained raw reads using the bam2FastQ program of the bamUtil package [8]. The CHD trio had a large number of read duplicates, which distorted the contamination fraction, so we deduplicated the aligned reads using the biobambam package<sup>3</sup>, and used the reads from the deduplicated file to generate the “contaminated” trio.

For each “real-world trio”, we repeated this procedure with  $\alpha = 0.01, 0.03, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5$ .

We aligned the “virtual specimen” and the “pure child” trio reads to the GRCh38DH reference genome following the 1000 Genomes pipeline [11]. Variants were called using Genome Analysis Toolkit 3.8 HaplotypeCaller with the option `-dontUseSoftClippedBases` and restricting the sequence considered to Gencode v.27 protein-coding exons with 50-nt flanks.

**2.5. Miscarriage samples.** Internal Review Board approval was obtained from the Ethics Committee of the Institute of Information Transmission Problems (document 11616-2116/726, 27/11/2017). Families who suffered a miscarriage and requested chromosomal microarray analysis (CMA) of the embryo were offered the choice to participate additionally in the whole-exome sequencing study. Informed consent was obtained from the parents. Only cases where no copy-number anomalies were detected by the CMA were considered for the WES study. Chorionic villi were used for the abortus DNA sample, while blood was drawn from both parents for sequencing. DNA was extracted using the Genra Puregene kit (Qiagen). The chromosomal microarray analysis was performed on the Thermo Fisher CytoScan Optima array. Copy-number analysis was performed using the ChAS 3.3 (Applied biosystems) software and an in-house database. Parenthood and the presence of fetal DNA in the chorionic villus sample were verified using short tandem repeat (STR) analysis with the CoDIS Plus system (GORDIZ, Russian Federation).

DNA was fragmented using Covaris S220 sonicator (Covaris, USA) using settings for 150-bp insert (peak power 175W, cy-

cles per burst 200, duty cycle 10%, time 280 seconds). Libraries were prepared using the TruSeq DNA Library Prep for Enrichment kit (Illumina, USA) without size selection (this step was replaced by purification/concentration with 1.5x volume of Ampure XP beads). Exome capture was performed using the xGen Exome Research Panel v.1.0 (IDT, USA) using manufacturer instructions with pooling of 12 libraries per reaction. Library concentration was measured on Qubit fluorometer (ThermoFisher, USA) and fragment length distribution was measured on Bioanalyzer2100 (Agilent, USA). 2.5 nM dilution of the resulting post-capture library was used for sequencing on the HiSeq4000 instrument (Illumina, USA) in paired-end mode with 150 cycles kit. The reads were aligned to the hg19 reference genome. The rest of the mapping and calling procedure was the same as for the “virtual specimen” trios (see Section 2.4).

### 3. Results

We compared the genotypes recalibrated by each of the MCC-aware methods on the “virtual specimen trios” (see Section 2.4) to the genotypes produced by the GATK HaplotypeCaller on the corresponding “pure child” trios, the latter being considered the ground truth. As a baseline, we also included the comparison to initial genotypes called by the GATK HaplotypeCaller on the “virtual specimen” trios (“no recalibration”). Since the “virtual specimen” generation procedure may be subject to hidden artifacts, e.g., arising from differences in the sequencing procedure of the original mother and the original child, we present the results separately for the four sets of “virtual specimen” trios generated from each “real-world” family.


The machine learning-based models were trained with a “leave-one-out” strategy, where every trio excluding the test trio was used for training. This ensures that we test on data derived from individuals unseen by the trained classifier.

Figure 2 summarizes the results separately for each publicly available family that served as the basis for the “virtual” contaminated trios, with the accuracy achieved by each method plotted against the contamination fraction. All three individual methods fare well, reducing the number of mis-called positions by 40-80% over the baseline of using the original MCC-unaware calls (the “no recalibration” approach). Both machine learning approaches outperform the confidence interval-based method and overcome some of the problems of that heuristic method. XGBoost is the best-performing individual method, while the meta-classifier outperforms all individual methods.

We also compared the running times of the methods for both training and testing (Table 1). In terms of speed, the confidence interval-based method, which requires no training, is the clear winner. The machine learning methods take on the order of minutes to train. Once the models are trained, though, the running times for recalibrating a specimen are comparable.

**3.1. Factors affecting the quality of machine learning-based genotype recalibration.** We further explored

<sup>3</sup><https://www.sanger.ac.uk/science/tools/biobambam>



**Fig. 2.** Accuracy of the recalibration methods at various MCC fractions. Machine learning methods were trained with a “leave one out” strategy. Each curve consists of twelve data points corresponding to accuracy of the method applied to “contaminated specimens” at various MCCs (the contamination values used are as given in Section 2.4). The accuracy is calculated on the intersection of the calls made on the virtual fetal specimen and the calls made on the real-world child.

**Table 1.** Training and running times of our methods. Training includes training a model on the entire synthetic dataset excluding the test trio (Section 2.4). Running involves recalibrating a single VCF file with a pre-trained model.

**Training time**

Logistic Regression	180 s
XGBoost	750 s
Meta-classifier	940 s

**Running time**

Logistic Regression	0.0025 s
XGBoost	0.34 s
Confidence Intervals	0.0021 s
Meta-classifier	0.35 s

the effect of various settings on the performance of the machine learning approaches.

As noted earlier, the training dataset needs to be sufficiently rich to succeed at genotype recalibration. To demonstrate this, the two machine learning algorithms were trained and tested on different pairs of families (a ‘one versus one’ approach), at all contamination fractions. The results are summarized in Figure S2. While all the methods lead to an improvement in accuracy, the gains are much more modest than when training with a ‘leave-one-out’ approach (Figure 2, contamination 0.3), due to overfitting to the features of a particular trio. To combat overfitting, we ultimately adopted the approach where we train on all available trios except for the test one.

The trained classifiers can tell us about the discriminative

**Table 2.** Top 10 most important features for machine learning methods in descending order. The parameters learned by the trained models (the coefficients of the hyperplanes separating the different classes for logistic regression; the degree of decision tree branching on each feature for XGBoost) can give an estimate of relative feature importance.

Logistic regression	XGBoost
1 Phred likelihood (0/0) (S)	Phred likelihood (0/0) (S)
2 Allelic depth (ref) (S)	Phred likelihood (1/1) (S)
3 Phred likelihood (1/1) (M)	MCC %
4 Allelic depth (alt) (S)	Phred likelihood (0/0) (M)
5 Phred likelihood (1/1) (S)	Phred likelihood (1/1) (M)
6 Phred likelihood (1/1) (M)	Allelic depth (ref) (S)
7 Genotype (0/1) (M)	Phred likelihood (1/1) (F)
8 Phred likelihood (0/1) (S)	Phred likelihood (0/0) (F)
9 Genotype (0/0) (M)	Allelic depth (alt) (S)
10 Allelic depth (alt) (M)	Read depth (F)



ties in the analysis of sequencing data for products of conception, which may be mixed with maternal tissue. We have shown that the accuracy of standard variant-calling pipelines does indeed degenerate as the maternal cell contamination increases, but that much of this decline can be alleviated by MCC-aware variant genotype correction. We show that the MCC fraction can be readily estimated from trio sequencing data and then used to inform the genotype correction. We show, using synthetic contaminated samples obtained from real trio data, that even a simple intuitive method based on confidence intervals does much to correct for the MCC-related loss of calling accuracy, and that the machine-learning methods trained on simulated data show even greater improvement, with the more sophisticated XGBoost having the better performance of the individual methods. The best performance, meanwhile, was obtained with the ensemble method that incorporates the results of all three methods that we tried.

We note that all methods discussed in this paper only recalibrate the variants that have been discovered by a general-purpose variant caller (we used GATK HaplotypeCaller which is commonly employed for human data analysis, but any variant caller which outputs sufficiently rich information about variants into a VCF file should work). Therefore, MCC-aware recalibration is a simple add-on to a standard bioinformatics pipeline, needing only the VCF file produced by it. The user can then compare the original VCF to the recalibrated VCF to see which genotypes had been changed. On the other hand, the reliance on standard variant calling implies that if MCC had caused the true fetal variant to be missed in all members of the trio, then that variant will not be called by the recalibration pipeline, either. We expect such cases to be rare.

We have applied our method to in-house sequencing data for three specimens from spontaneous miscarriages. While these particular samples had rather low MCC, this may not always be the case, as high levels of MCC do occur among amniocentesis and chorionic villi samples.

Currently, next-generation sequencing is applied to fetal DNA obtained by invasive methods which extract amniotic fluid or fetal or chorionic villi cells. Our work is aimed at the analysis of this sort of sequencing data, and we do not consider MCC fractions higher than 50%. As its costs drop, sequencing may become a practical option in non-invasive prenatal testing (NIPT) as well. NIPT analyzes fetal DNA circulating in maternal blood which constitutes a small fraction of the DNA sample obtained. Analyzing that sort of data would make MCC-aware variant calling a necessity, and may in fact give rise to more sophisticated and/or specialized algorithms, such as those that work directly with mapped reads.

## Supplementary material

Supplementary material is available at *bioRxiv* online. We also present a repository with scripts and notebooks for reproducing our experiments as well as applying our methods: <https://github.com/bazykinlab/ML-maternal-cell-contamination>

## Funding

The work was funded by the Skoltech Biomedical Initiative grant to GAB and DY.

## References

1. Sunayna Best, Karen Wou, Neeta Vora, Ignatia B. Van der Veyver, Ronald Wapner, and Lyn S. Chitty. Promises, pitfalls and practicalities of prenatal whole exome sequencing. *Prenatal diagnosis*, 38(1):10–19, January 2018.
2. Tianqi Chen and Carlos Guestrin. Xgboost: A scalable tree boosting system. pages 785–794, 2016.
3. The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature*, 526(7571):68–74, October 2015.
4. Manuel Corpas, Willy Valdivia-Granda, Nazareth Torres, Bastian Greshake, Alain Coletta, Alexej Knaus, Andrew P. Harrison, Mike Cariaso, Federico Moran, Fiona Nielsen, Daniel Swan, David Y. Weiss Solís, Peter Krawitz, Frank Schacherer, Peter Schols, Huangming Yang, Pascal Borry, Gustavo Glusman, and Peter N. Robinson. Crowdsourced direct-to-consumer genomic analysis of a family quartet. *BMC Genomics*, 16(1):910, November 2015.
5. Christopher DeBoever, Matthew Aguirre, Yosuke Tanigawa, Chris C. A. Spencer, Timothy Poterba, Carlos D Bustamante, Mark J. Daly, Matti Pirinen, and Manuel A Rivas. Bayesian model comparison for rare variant association studies of multiple phenotypes. *bioRxiv*, 2018.
6. Jacob F. Degner, John C. Marioni, Athma A. Pai, Joseph K. Pickrell, Everlyne Nkadori, Yoav Gilad, and Jonathan K. Pritchard. Effect of read-mapping biases on detecting allele-specific expression from RNA-sequencing data. *Bioinformatics*, 25(24):3207–3212, December 2009.
7. Zhen Jia, Mao Fengbiao, Lu Wang, Mingzhen Li, Yueyi Shi, Baorong Zhang, and Guolan Gao. Whole-exome sequencing identifies a de novo mutation in *trpm4* involved in pleiotropic ventricular septal defect. 10:5092–5104, 05 2017.
8. Goo Jun, Mary Kate Wing, Gonçalo R. Abecasis, and Hyun Min Kang. An efficient and scalable analysis framework for variant extraction and refinement from population scale DNA sequence data. *Genome Research*, page gr.176552.114, April 2015.
9. Allen N. Lamb, Jill A. Rosenfeld, Justine Coppinger, Erin T. Dodge, Mindy Preston Dabell, Beth S. Torchia, J. Britt Ravnán, Lisa G. Shaffer, and Blake C. Ballif. Defining the impact of maternal cell contamination on

the interpretation of prenatal microarray analysis. *Genetics in Medicine*, 14(11):914–921, November 2012.

Extensive sequencing of seven human genomes to characterize benchmark reference materials. *Scientific Data*, 3:160025, June 2016.

10. Narasimhan Nagan, Nicole E. Faulkner, Christine Curtis, and Iris Schrijver. Laboratory Guidelines for Detection, Interpretation, and Reporting of Maternal Cell Contamination in Prenatal Analyses. *The Journal of Molecular Diagnostics : JMD*, 13(1):7–11, January 2011.
11. 1000 Genomes Project. Grch38 alignment readme, 2015. [https://github.com/igsr/1000Genomes\\_data\\_indexes/blob/master/data\\_collections/1000\\_genomes\\_project/README.1000genomes.GRCh38DH.alignment](https://github.com/igsr/1000Genomes_data_indexes/blob/master/data_collections/1000_genomes_project/README.1000genomes.GRCh38DH.alignment).
12. Taita Stojilkovic-Mikic, Kathy Mann, Zoe Docherty, and Caroline Mackie Ogilvie. Maternal cell contamination of prenatal samples assessed by QF-PCR genotyping. *Prenatal Diagnosis*, 25(1):79–83, 2005.
13. Ahmad N. Abou Tayoun, Nancy B. Spinner, Heidi L. Rehm, Robert C. Green, and Diana W. Bianchi. Prenatal DNA Sequencing: Clinical, Counseling, and Diagnostic Laboratory Considerations. *Prenatal Diagnosis*, 38(1):26–32, January 2018.
14. Geraldine Van der Auwera. (howto) apply hard filters to a call set, 2013. <https://gatkforums.broadinstitute.org/gatk/discussion/2806/howto-apply-hard-filters-to-a-call-set>, Edited November 2018.
15. Jennifer Weida, Avinash S. Patil, Frank P. Schubert, Gail Vance, Holli Drendel, Angela Reese, Stephen Dlouhy, Shaochun Bai, and Men-Jean Lee. Prevalence of maternal cell contamination in amniotic fluid samples. *The Journal of Maternal-Fetal & Neonatal Medicine*, 30(17):2133–2137, September 2017.
16. Justin M. Zook, David Catoe, Jennifer McDaniel, Lindsay Vang, Noah Spies, Arend Sidow, Ziming Weng, Yuling Liu, Christopher E. Mason, Noah Alexander, Elizabeth Henaff, Alexa B. R. McIntyre, Dhruva Chandramohan, Feng Chen, Erich Jaeger, Ali Moshrefi, Khoa Pham, William Stedman, Tiffany Liang, Michael Saghbini, Zeljko Dzakula, Alex Hastie, Han Cao, Gintaras Deikus, Eric Schadt, Robert Sebra, Ali Bashir, Rebecca M. Truty, Christopher C. Chang, Natali Gulbahce, Keyan Zhao, Srinka Ghosh, Fiona Hyland, Yutao Fu, Mark Chaisson, Chunlin Xiao, Jonathan Trow, Stephen T. Sherry, Alexander W. Zaranek, Madeleine Ball, Jason Bobe, Preston Estep, George M. Church, Patrick Marks, Sofia Kyriazopoulou-Panagiotopoulou, Grace X. Y. Zheng, Michael Schnall-Levin, Heather S. Ordonez, Patrice A. Mudivarti, Kristina Giorda, Ying Sheng, Karoline Bjarnesdatter Rypdal, and Marc Salit.